InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.750 0.01 (1.35%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$316 DEP presentation at SNMMI radiopharmaceuticals conference 11 Jun 2024 4:09PM $0.100 $0.750 risen by 650%
$316 Notification regarding unquoted securities - SPL 11 Jun 2024 1:51PM $0.100 $0.750 risen by 650%
$316 DEP irinotecan presentation at ASCO 2024 Annual Meeting 4 Jun 2024 1:56PM $0.103 $0.750 risen by 631.71%
$316 DEP cabazitaxel presentation at ASCO 2024 Annual Meeting 3 Jun 2024 4:11PM $0.110 $0.750 risen by 581.82%
$316 Change in Director's Interest Notice - Cheryl Maley 30 May 2024 4:27PM $0.115 $0.750 risen by 552.17%
$316 Change in Director's Interest Notice - R Thomas 30 May 2024 11:06AM $0.115 $0.750 risen by 552.17%
$316 Positive final DEP irinotecan Phase 2 clinical trial results 27 May 2024 10:15AM $0.115 $0.750 risen by 552.17%
$316 Starpharma Business Update 22 May 2024 10:26AM $0.110 $0.750 risen by 581.82%
$316 Investor Webinar Notification - SPL Business Update 20 May 2024 10:27AM $0.115 $0.750 risen by 552.17%
$316 Change in substantial holding 16 May 2024 4:48PM $0.115 $0.750 risen by 552.17%
$316 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 9:42AM $0.135 $0.750 risen by 455.56%
$316 Change in Director's Interest Notice - R Thomas 17 Apr 2024 3:03PM $0.130 $0.750 risen by 476.92%
$316 Change in Director's Interest Notice - R Basser 16 Apr 2024 2:09PM $0.125 $0.750 risen by 500%
$316 Change in Director's Interest Notice - R Thomas 15 Apr 2024 2:17PM $0.130 $0.750 risen by 476.92%
$316 Investor Webinar Notification SPL Medicxi Partnership 8 Apr 2024 10:02AM $0.125 $0.750 risen by 500%
$316 Starpharma and Medicxi Partnership Petalion Therapeutics 8 Apr 2024 9:25AM $0.125 $0.750 risen by 500%
$316 S&P DJI Announces March 2024 Quarterly Rebalance 1 Mar 2024 5:03PM $0.130 $0.750 risen by 476.92%
$316 Half Yearly Report and Accounts 28 Feb 2024 9:38AM $0.130 $0.750 risen by 476.92%
$316 VivaGel BV US FDA Appeal Outcome 19 Feb 2024 9:37AM $0.145 $0.750 risen by 417.24%
$316 Application for quotation of securities - SPL 6 Feb 2024 2:05PM $0.145 $0.750 risen by 417.24%
$316 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 9:34AM $0.150 $0.750 risen by 400%
$316 Viraleze shows antiviral efficacy in COVID-19 patients 29 Jan 2024 9:16AM $0.145 $0.750 risen by 417.24%
$316 VivaGel BV sales and distribution agreement MENA region 22 Jan 2024 1:15PM $0.155 $0.750 risen by 383.87%
$316 DEP cabazitaxel data presentation at ASCO GI cancer meeting 19 Jan 2024 10:18AM $0.150 $0.750 risen by 400%
$316 Notification of cessation of securities - SPL 12 Jan 2024 2:13PM $0.165 $0.750 risen by 354.55%

101 - 125 of 866 results

Page 5 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.